The specter of generic challenges has repeatedly loomed above copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the outlook of similar pharmaceutical holdings. While initial times saw substantial gains, the exclusivity end has allowed the way for less expensive alternatives, potentially reducing earnings and presenting a ge